PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35519003-8	2022	As CUL4A needs to be activated by neddylation to facilitate the degradation of several proteins including PCNA, we propose a novel explanation for the synergism between cytarabine and the neddylation inhibitor pevonedistat by inhibition of translesion synthesis.	pevonedistat	210-222	cullin 4A	Homo sapiens	3-8	
35428778-5	2022	Further analysis revealed that the specific pevonedistat target CUL4A played an essential role in driving the synergy of the pevonedistat and cisplatin combination.	pevonedistat	44-56	cullin 4A	Homo sapiens	64-69	
35428778-5	2022	Further analysis revealed that the specific pevonedistat target CUL4A played an essential role in driving the synergy of the pevonedistat and cisplatin combination.	pevonedistat	125-137	cullin 4A	Homo sapiens	64-69	
35428778-9	2022	Our findings provide strong rationale for clinical investigation of CUL4A inhibition with pevonedistat as a novel strategy to augment the efficacy of cisplatin therapy for patients with HNSCC and identify loss of DDB2 as a key pharmacodynamic mediator controlling sensitivity to this regimen.	pevonedistat	90-102	cullin 4A	Homo sapiens	68-73	
24245672-8	2013	Treatment with MLN4924, an adenosine sulfamate analog which hinders the NEDD8 activating enzyme NAE1, blocked neddylation of cullin4A (CUL4A).	pevonedistat	15-22	cullin 4A	Homo sapiens	125-133	
24245672-8	2013	Treatment with MLN4924, an adenosine sulfamate analog which hinders the NEDD8 activating enzyme NAE1, blocked neddylation of cullin4A (CUL4A).	pevonedistat	15-22	cullin 4A	Homo sapiens	135-140